ClinicalTrials.gg

Primary Myelofibrosis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 627 studies for Primary Myelofibrosis across more than 10 countries. 126 are recruiting or about to start. 271 of them are mainly about Primary Myelofibrosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 655 studies for Primary Myelofibrosis. How that becomes 623 here

This page counts the studies the registry files under Primary Myelofibrosis, and those it files under no condition that list Primary Myelofibrosisthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 655Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −13List Primary Myelofibrosis as a condition, but the registry did not file them under itMost often written as “Secondary Myelofibrosis” (4), “Myelofibrosis,MF” (2), and “Advanced Myelofibrosis” (1). The registry filed them under other conditions only, most often Myeloproliferative Disorders (8) and Leukemia, Myeloid, Acute (6).
  3. −19Match it another way18 name it in the title and 1 in a keyword.
  4. 623The count on this page3 of them list Primary Myelofibrosis in their own words; the registry filed them under no condition.

Status

Completed
309
Recruiting
102
Terminated
95
Active, not recruiting
49
Withdrawn
28
Not yet recruiting
21

Phase

Phase 2
282
Phase 1
202
Phase 3
58
Early Phase 1
9
Phase 4
4

Where

United States
453
Italy
101
Germany
75
France
72
Canada
63
United Kingdom
61

Who develops what

Add Primary Myelofibrosis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 14 programs from 12 companies, 9 with this as their studies’ main aim; 2 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Incyte, Novartis and Chengdu Zenitar Biomedical Technology here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
ruxolitinibRecent, repeated
Evidence
  • NCT07357727 · Novartis · Phase 3 · live · background · “Ruxolitinib” · registered Jan 2026
  • NCT06479135 · Ipsen · Phase 3 · live · background · “Ruxolitinib” · registered Jun 2024
  • NCT06397313 · Ryvu Therapeutics SA · Phase 2 · background · “Ruxolitinib” · registered Apr 2024
  • NCT05980806 · Karyopharm Therapeutics Inc · Phase 2 · live · background · “Ruxolitinib” · registered Jul 2023
  • NCT05280509 · Telios Pharma, Inc. · Phase 2 · live · background · “Ruxolitinib” · registered Mar 2022
Incyte Corporation72% of its industry studiesUS: Incyte Corporation (FDA 2011)EU: Novartis (EMA 2012) + 1 other55 studies

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
pelabresib☆ Track2 live phase-3 studies: NCT07357727, NCT04603495Novartis
elritercept☆ Track1 live phase-3 study: NCT07623161Takeda

The 2 in phase 3 with the nearest primary completion, of 14 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.JAK2 Inhibitor TQ05105 · Sino Biopharmaceutical Limited · Phase 2 main aimNCT06122831 A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) — primary endpoint: Maximal tolerance dose (MTD) · 92 enrolled
  • 30 Apr 2027 est.nuvisertib · Sumitomo Pharma Co., Ltd. · Phase 2 main aimstudied with ruxolitinibstudied with momelotinibNCT04176198 A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis — primary endpoint: Determine the incidence of dose-limiting toxicities (DLTs) · 240 enrolled
  • 31 Oct 2027 est.ruxolitinib · suzhou junjing biosciences co ltd · Phase 2 main aimNCT06909136 A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis — primary endpoint: AE · 33 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Primary Myelofibrosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 22 open · JAK inhibitors 19 open · Antimetabolites 4 open · Alkylating agents 3 open · Calcineurin inhibitors 2 open

Coming up

61studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger. 10 (10%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 7 (7%) take healthy volunteers.

Recruiting studies that take each age, of 102
AgeWomenMen
107 (7%)7 (7%)
1897 (95%)97 (95%)
3099 (97%)99 (97%)
4099 (97%)99 (97%)
5099 (97%)99 (97%)
65100 (98%)100 (98%)
7597 (95%)97 (95%)
8587 (85%)87 (85%)

Across all 627 studies, recruiting or not: 23% stop at 75 or younger and 10% at 65; 21% take children; 0% are for women only and <1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Primary Myelofibrosis studies take

Of 98 phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 66 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 152 mo31–103 · 68 studies——
Phase 1/269 mo52–125 · 26 studies——
Phase 266 mo32–111 · 98 studies32 mo25–66 · 30 studies83 mo42–119 · 68 studies
Phase 339 mo30–68 · 22 studies——
Observational34 mo29–119 · 23 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 627. Browse all 627 → or search them.